STOCK TITAN

Vir Biotechnology Inc - VIR STOCK NEWS

Welcome to our dedicated news page for Vir Biotechnology (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vir Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vir Biotechnology's position in the market.

Rhea-AI Summary
Vir Biotechnology nominates Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors, showcasing commitment to ongoing Board refreshment. The new directors bring extensive clinical development and computational expertise, with Dr. Bischofberger having overseen the approval of over 25 medicines and Dr. Farid leading advanced computational methods for therapy development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Vir Biotechnology, Inc. (VIR) will announce its first-quarter financial results on May 2, 2024, followed by a conference call. The update will be available on their website. Investors can join the call via webcast or phone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. appoints Dr. Charlotte Hubbert as Vice President of Corporate Development, bringing extensive experience in cell therapy research and venture investment. Dr. Hubbert's background includes leadership roles at Gates Foundation Venture Capital and NanoString Technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
management
Rhea-AI Summary
Vir Biotechnology (VIR) completes enrollment in Phase 2 SOLSTICE trial for chronic hepatitis delta treatment ahead of schedule. Initial data expected in Q2 2024. Approximately 50% of participants have compensated cirrhosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
-
Rhea-AI Summary
Vir Biotechnology, Inc. (VIR) will be participating in key investor conferences in March, with Marianne De Backer, CEO, engaging in fireside chats and one-on-one meetings. The events aim to enhance investor relations and showcase the company's progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.94%
Tags
conferences
-
Rhea-AI Summary
Vir Biotechnology, Inc. provided a corporate update and financial results for Q4 and full year 2023. The Phase 2 SOLSTICE trial in chronic hepatitis delta participants showed promising results with 100% achieving HDV RNA less than LLQ. The Phase 2 MARCH Part B data for chronic hepatitis B demonstrated positive outcomes. Vir has $1.63 billion in cash, cash equivalents, and investments as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.94%
Tags
Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) announced the departure of Chief Medical Officer Dr. Phil Pang in March 2024 to focus on family. The company is searching for a successor. Dr. Pang's contributions to the development of sotrovimab during the COVID-19 pandemic are highlighted. Vir's CEO praised his work in infectious diseases and team building for global health needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
-
Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) will release its fourth-quarter financial results on February 22, 2024, and host a conference call to discuss the corporate update. The press release and webcast will be accessible on the company's website. A recorded version of the call will be available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
-
Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) is focusing on chronic hepatitis delta and chronic hepatitis B clinical programs and antibody platform to target infectious diseases, autoimmune diseases, and oncology. The company is reducing its workforce by approximately 12% and consolidating its geographic footprint, anticipating annual savings of at least $40 million from cost optimization efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
Rhea-AI Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) CEO Marianne De Backer to present at J.P. Morgan 2024 42nd Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
Vir Biotechnology Inc

Nasdaq:VIR

VIR Rankings

VIR Stock Data

1.21B
88.97M
14.23%
76.27%
3.67%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Francisco

About VIR

vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.